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Advances in automation have facilitated the widespread adoption of high-
throughput vapour-diffusion methods for initial crystallization screening.
However, for many proteins, screening thousands of crystallization conditions
fails to yield crystals of sufﬁcient quality for structural characterization. Here,
the rates of crystal identiﬁcation for thaumatin, catalase and myoglobin using
microﬂuidic Crystal Former devices and sitting-drop vapour-diffusion plates are
compared. It is shown that the Crystal Former results in a greater number
of identiﬁed initial crystallization conditions compared with vapour diffusion.
Furthermore, crystals of thaumatin and lysozyme obtained in the Crystal Former
were used directly for structure determination both in situ and upon harvesting
and cryocooling. On the basis of these results, a crystallization strategy is
proposed that uses multiple methods with distinct kinetic trajectories through
the protein phase diagram to increase the output of crystallization pipelines.
1. Introduction
Protein crystals are generated by perturbing the solubility of a con-
centrated pure protein solution through the addition of precipitating
reagents such as salts, polymers and other additives that promote
crystal nucleation and growth (McPherson et al., 1995). In addition
to precipitant selection, which is critical to protein crystallization
(Kimber et al., 2003; Newman et al., 2005; Page et al., 2003), the
method by which the precipitant is introduced to the protein solution
also has a signiﬁcant impact on crystal formation and quality (Garcı ´a-
Ruiz, 2003; Gavira et al., 2002). For example, convection-free envir-
onments, achieved under microgravity, within hydrogels or inside thin
capillary tubes, promote the growth of highly ordered crystals of
superior quality (Lorber et al., 1999; Vergara et al., 2005). Further-
more, ﬂuid physics at the microscale allows gentle and well controlled
diffusive mixing of solutions. Many studies have established that a
diffusive mixing regime facilitates the crystallization process (Dhouib
et al., 2009; Emamzadah et al., 2009; Hansen et al., 2002; Ng et al.,
2003, 2008).
Capitalizing on the advantages of convection-free diffusion for
protein crystallization, various microﬂuidic devices have been devel-
oped and shown to improve protein-crystallization output (Anderson
et al., 2007; Garcia-Ruı ´z et al., 2002; Gavira et al., 2002; Hansen et al.,
2004, 2006; Li et al., 2010; Yadav et al., 2005). In this study, we evaluate
the impact of employing a commercially available microﬂuidic device,
the Crystal Former (Fig. 1), on initial screening of several well
characterized proteins. We have performed crystallization trials using
the Crystal Former in parallel with vapour diffusion for the crystal-
lization of thaumatin, catalase and myoglobin. Furthermore, we
assess the validity of claims that crystals grown in this device can be
harvested for data collection and yield crystals of high quality that
can be used directly for structure determination. In doing so, we have
determined the structure of thaumatin from crystals harvested from
the Crystal Former and of lysozyme via in situ diffraction experi-
ments.2. Materials and metods
2.1. Model protein preparation
Thaumatin from Thaumatococcus daniellii (Sigma, catalog No.
T7638) was dissolved in distilled water to 50 mg ml
 1. Catalase and
myoglobin (Sigma, USA) were solubilized in distilled water to 30 and
62 mg ml
 1, respectively. Lysozyme was purchased from Hampton
Research (catalog No. HR7-108) and was reconstituted to a ﬁnal
concentration of 20 mg ml
 1 in distilled water.
2.2. Crystallization of thaumatin, catalase and myoglobin by sitting-
drop vapour diffusion
The crystallization conditions for thaumatin, catalase and myo-
globin were determined using conditions 1–48 of the Crystal Screen
(Hampton Research, USA) and 1–48 of the JCSG-plus (Molecular
Dimensions, UK) sparse-matrix screens. For sitting-drop vapour
diffusion, 0.5 ml protein solution was mixed with 0.5 ml crystallization
solution and equilibrated against 100 ml of the crystallization condi-
tion in the reservoir. Sitting-drop plates were sealed with Crystal
Clear tape (Hampton Research, USA) and incubated at room
temperature for 7 d.
2.3. Crystallization of thaumatin, myoglobin and catalase by liquid–
liquid diffusion
The Crystal Formers (Microlytic; http://www.microlytic.com) used
in this study each comprised 16 microchannels. Each channel is
bounded by two sample-inlet wells. Protein sample was ﬁrst applied
and the channel was allowed to ﬁll by capillary action. The precipitant
solution was then applied to the opposing inlet and the experiment
was sealed. No external equipment controls sample loading in this
format. All three proteins were screened using the Crystal Former in
parallel with vapour-diffusion trials. For these trials, 0.3 ml protein
sample was applied to each channel followed by the loading of 0.3 ml
crystallization reagent into the opposing inlet. The Crystal Formers
were then sealed with the sealing tape provided and incubated at
room temperature for 7 d. The crystallization trials were inspected
manually.
2.4. Harvesting of thaumatin crystals from the Crystal Former
Thaumatin crystals grown from Crystal Screen condition No. 29
(0.1 M HEPES pH 7.5,0.8 M potassium sodium tartrate tetrahydrate)
were selected for data collection. Access to the crystals was accom-
plished by scoring the sealing ﬁlm on the back of the Crystal Former
with a scalpel. Once exposed, 5 ml of cryoprotectant was added to the
open channel to prevent drying of the crystal during manipulations
and to protect the crystal during subsequent ﬂash-cooling. Cryo-
protectant solutions were generated by combining the respective
crystallization condition with an equal volume of 50%(v/v) glycerol
that had been prepared in distilled water. Thaumatin crystals were
harvested using nylon loops (Hampton Research, USA). Crystals
were ﬂash-cooled and stored in liquid nitrogen for subsequent data
collection. Diffraction properties were evaluated on the X6A beam-
line at National Synchrotron Light Source (Brookhaven National
Laboratory, Upton, New York, USA) and complete data sets were
collected for suitable crystals.
2.5. Crystallization and in situ diffraction analysis of lysozyme
crystals in the Crystal Former
Given the improved crystallization hit rates obtained in the Crystal
Former (Microlytic; http://www.microlytic.com), we wanted to eval-
uate whether the device was UV-compatible so that protein crystals
formed in it could be detected in situ using a UV microscope (JAN
Scientiﬁc, USA). The Crystal Former and the channels were imaged
by placing the microﬂuidic device in a slide holder mounted on the
XY stage of a UVEX microscope. Crystals were imaged using both
the 5  and 15  objectives.
2.6. Data collection, processing and structure determination of
thaumatin and lysozyme
All data were collected at 100 K on the X6A beamline of the
National Synchrotron Light Source (Brookhaven National Labora-
tory, Upton, New York, USA). Complete data sets each consisting
of 300 frames of 1  oscillations were recorded using an ADSC Q210
detector. The exposure time was 30 s and the crystal-to-detector
distance was 200 mm. Data processing and scaling was performed
with HKL-3000 (Minor et al., 2006). Solvent content was computed
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Figure 1
A microﬂuidic device comprised of 16 microchannels. Using conventional pipettes, the protein sample is loaded into one sample inlet and the crystallization solution is
applied to the opposing channel. The inlets are sealed and the Crystal Former is incubated at the desired temperature. A thin removable sealing ﬁlm forms the rear of each
microchannel, permitting crystal access for harvesting and X-ray diffraction studies.using the CCP4 package (Winn et al., 2011; Matthews, 1968;
Kantardjieff & Rupp, 2003). The structures were determined by
molecular replacement using MOLREP (Vagin & Teplyakov, 2010).
Reﬁnement consisted of repeated cycles of model building in Coot
(Emsley & Cowtan, 2004) and reﬁnement in REFMAC (Murshudov
et al., 2011). The search models were PDB entries 2vi3 for thaumatin
(Asherie et al., 2009) and 2cgi for lysozyme (Jakoncic et al., 2006).
3. Results
3.1. Diffusive mixing kinetics increased crystallization productivity
relative to vapour diffusion for well characterized proteins
Thaumatin, catalase and myoglobin were screened with a subset
of solutions from the sparse-matrix screens Crystal Screen (48
conditions) and JCSG-plus (48 conditions) in parallel in sitting-drop
vapour-diffusionplatesandCrystal Formerdevices.Allthree proteins
yielded crystals in both methods. Remarkably, there were signiﬁcant
differences in the identities and numbers of crystallization conditions
for the Crystal Former and sitting-drop experiments. For trials with
the Crystal Former, crystals were obtained for 5, 28 and 8% of
all conditions for thaumatin, catalase and myoglobin, respectively.
The success rates were 1, 7 and 1% for thaumatin, catalase and
myoglobin, respectively, using sitting-drop vapour diffusion. Conse-
quently, a fourfold to eightfold increase in success for initial
crystallization trials was observed in the Crystal Former (Table 1).
A comparison of the identiﬁed crystallization conditions revealed
striking differences between vapour diffusion and the microﬂuidic
device (Fig. 2). Approximately 40% of the conditions identiﬁed by
vapour diffusion were unique to that method and were not captured
in the Crystal Former trials. Similarly, 90% of the crystals grown in
the Crystal Former were not identiﬁed by the sitting-drop experi-
ments, highlighting the advantages of the Crystal Former in sampling
the protein phase space.
To verify that the crystals obtained using the Crystal Former were
indeed protein crystals, a representative subset was harvested and
their respective diffraction was analyzed on the X6A beamline at the
National Synchrotron Light Source (Brookhaven National Labora-
tory, Upton, New York. USA). For each mounted crystal, several
frames were collected in order to verify that these were indeed
protein crystals. The maximal resolution obtained from these crystals
ranged from 2.8 to 1.1 A ˚ , highlighting the good diffraction quality of
the extracted crystals.
3.2. Harvesting and structure determination of thaumatin
Thaumatin crystals were grown and prepared for data collection
as described previously (Fig. 3a). A single crystal was mounted in a
cryoloop and cooled in liquid nitrogen. A complete set of diffraction
data was collected and the structure was determined by molecular
replacement (Fig. 3b). Electron density was apparent for 206 of the
207 amino-acid residues. The thaumatin structure was reﬁned to
1.25 A ˚ resolution, with R and Rfree values of 15.4% and 16.9%,
respectively (Table 2). A single thaumatin monomer was modelled in
the asymmetric unit, along with 201 water molecules and ten tartrate
ions. This crystal form was isomorphous to 11 structures previously
deposited in the Protein Data Bank (1lr3, 1rqw, 2blr, 2blu, 2d8p, 2g4y,
2oqn, 2vi2, 3dzp, 3dzr and 3e0a). For these depositions, the resolution
ranged from 1.05 to 2.3 A ˚ and the Rfree values spanned the range
15.2–25%. As observed in the thaumatin structure reported here, no
density was observed for the C-terminal alanine in PDB entries 2blr
and 2blu. The remaining entries report unambiguous density for all
207 residues of thaumatin.
3.3. In situ data collection and structure determination for lysozyme
The Crystal Formers were also assessed for their compatibility with
in situ X-ray analysis on the X6A beamline (National Synchrotron
Light Source, Brookhaven National Laboratory). The Crystal Former
was mounted lengthwise with the microchannels perpendicular to the
goniometric head. Not only could the Crystal Formers be mounted
for the identiﬁcation of protein crystals, but a complete data set for
lysozyme crystals contained within the microchannels could be
collected in situ at room temperature (Fig. 3c, Table 2). The crystal
structure of lysozyme was determined at 1.65 A ˚ resolution with R and
Rfree values of 17.2% and 22.2% for the ﬁnal reﬁned structure. These
crystals were isomorphous to 78 previous PDB entries. The resolution
of previously deposited lysozyme structures ranged from 0.94 to
3.9 A ˚ , with Rfree values ranging from 14.5 to 32.3%.
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Table 1
Relative increase in crystallization outcomes for catalase, myoglobin and thaumatin
using the Crystal Former and vapour-diffusion methods.
No. of crystallization conditions
Protein Crystal Former Vapor diffusion Improvement (fold)
Catalase 28 7 4
Myoglobin 8 1 8
Thaumatin 5 1 5
Figure 2
Each protein was screened by Crystal Screen (Hampton Research) and JCSG-plus 1 (Molecular Dimensions, UK) crystal screening using both sitting-drop vapour diffusion
and the Crystal Former. Crystallization conditions identiﬁed with the Crystal Former are shown in green. Vapour-diffusion crystals are shown in red.3.4. Compatibility of the Crystal Former with in situ UV analysis
A commonly used approach for imaging protein-crystallization
experiments is UV ﬂuorescence. The amino acid tryptophan emits
light at approximately 360 nm when excited with light of 280 nm;
hence, if a target protein contains the amino acid tryptophan it should
be possible to distinguish target protein crystals from precipitant
crystals based on ﬂuorescence. Lysozyme crystals (10–100 mm) were
grown in the Crystal Former and the channels were imaged by placing
the microﬂuidic device in a slide holder mounted on the XY stage of
a UVEX microscope (JAN Scientiﬁc, USA). Fluorescence from the
larger crystals (>100 mm) could be visualized with the 5  objective,
whereas the small crystals ( 10 mm) could only be seen with the 15 
objective by virtue of the higher ﬂuorescence excitation, collection
efﬁciency and higher spatial resolution of the higher power objective
(Fig. 3d). The background signal and UV absorption from the
material of the Crystal Former was sufﬁciently low that ﬂuorescence
from even the smallest crystals could be detected reliably.
4. Discussion
In this study, we have explored the value of using an alternative
method to vapour diffusion for initial crystallization screening,
namely liquid–liquid diffusion using the Crystal Former. We have
been able to identify crystallization conditions using both the vapour-
diffusion and liquid–liquid diffusion methods, with more crystal-
lization conditions resulting from the latter method for all proteins
systematically sampled in this work. It should be noted that many of
the conditions identiﬁed were unique to the respective method and
were not captured by the alternate method (Fig. 2). Various studies of
crystallization rates by vapour diffusion indicate that proteins that
are crystallizable typically do so within a relatively small number of
conditions (Kimber et al., 2003; Page et al., 2003). Further exploration
of crystallization conditions using the same technique reaches a point
of diminishing returns whereby further exploration of additional
chemical conditions becomes less likely to yield crystals. The
increased number of crystallization conditions identiﬁed in this study
laboratory communications
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Figure 3
(a) Crystals of thaumatin were grown from 0.8 M potassium sodium tartrate, 0.1 M HEPES pH 7.5 in the Crystal Former. Here they are shown under polarized light. (b)
Representative 2Fo   Fc electron density for the reﬁned thaumatin structure at 1.25 A ˚ resolution shown with 1.5  contours. (c) The diffraction pattern of lysozyme crystals
grown in the Crystal Former. X-ray data were collected in situ at room temperature on the X6A beamline (National Synchrotron Light Source, Brookhaven National
Laboratory, Upton, New York, USA). (d) Detection of protein crystals in the Crystal Former using a UVEX microscope. Brightﬁeld (left) and UV-ﬂuorescence (right)
images of lysozyme crystals within the microchannels of the Crystal Formers are shown. The microchannel width is 150 mm and the exposure lengths were 0.5 and 1 s for the
brightﬁeld and ﬂuorescence images, respectively.using the liquid–liquid diffusion method further underscores the
important contribution that alternative kinetic trajectories through
protein phase space have on the success of crystallization in a given
condition. We propose that a more effective strategy for initial
crystallization screening would thus be to explore the same chemical
space using different crystallization methodologies.
A variety of crystallization formats, including liquid–liquid diffu-
sion, offer unique kinetic trajectories through the protein phase
diagram. A comprehensive screening approach that incorporates
multiple crystallization formats would therefore be expected to
promote the increased identiﬁcation of crystallization conditions
relative to single-technique approaches. Indeed, the data presented
here revealed remarkable differences in crystallization behaviour for
proteins screened in parallel using Crystal Formers and sitting-drop
vapour diffusion. The unique sampling of the protein phase diagram
for each crystallization method underlies the distinctive crystal-
lization behaviour observed for these proteins. This resulted in
signiﬁcant differences in crystallization rates, with a pronounced
increase in crystallization conditions identiﬁed in the Crystal Former
trials with all other screening variables constant. The improved
mixing kinetics and sampling of the protein phase space, coupled with
the compatibility of the Crystal Former to most experimental setups,
makes this device well suited as a standard approach to complement
the current workﬂow of both academic and industrial crystallography
laboratories.
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Table 2
Data collection and structure reﬁnement.
Values in parentheses are for the highest resolution shell.
Thaumatin
(in loop, 100 K)
Lysozyme (in device,
room temperature)
Data reduction
Wavelength (A ˚ ) 0.9537 0.9793
Space group P41212 P43212
Resolution (A ˚ ) 25.00–1.25 (1.27–1.25) 20.00–1.65 (1.68–1.65)
Unit-cell parameters (A ˚ ) a = b = 57.91, c = 150.13 a = b = 79.15, c = 38.02
hI/ (I)i 31.0 (1.8) 22.3 (2.0)
Completeness (%) 99.7 (95.9) 90.2 (94.3)
Rmerge† (%) 5.3 (49.9) 5.9 (47.4)
Multiplicity 7.7 (3.6) 2.9 (2.8)
Mosaicity ( ) 0.21 0.15
Solvent content (%) 48 31
No. of frames 360 35
Oscillation per frame ( ) 0.3 1
Reﬁnement
Resolution (A ˚ ) 23.00–1.25 (1.28–1.25) 19.20–1.65 (1.69–1.65)
Rwork‡/Rfree§ (%) 15.4/16.9 17.2/22.2
No. of protein residues/atoms 206/1570 129/997
No. of tartrate atoms 10 [1 TAR}]0
No. of waters 201 101
Average B (A ˚ 2) 12.00 21.67
Protein only 10.99 20.29
Tartrate ion 8.89 —
Solvent 19.98 36.5
R.m.s.d.††
Bonds (A ˚ ) 0.012 0.015
Angles ( ) 1.461 1.665
PDB entry 3qy5 3qy4
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the ith intensity
measurement of reﬂection hkl, including symmetry-related reﬂections, and hI(hkl)i is its
average. ‡ R =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj, where Fobs and Fcalc are the observed
and calculated structure factors, respectively. § Rfree was calculated using 5% of the
diffraction data, selected at random, which were excluded from reﬁnement. } TAR
refers to one tartrate ion. †† Root-mean-square deviation.